Patient Demographics. by James M. Friedman (22522150)

Subjects:

Pain and Function Outcomes Following PM Tenotomy. by James M. Friedman (22522150)

Subjects:

Diagnostic Criteria for Human Disharmony Loop. by James M. Friedman (22522150)

Subjects:

Normal Anatomy vs. Disharmonic Pathoanatomy. by James M. Friedman (22522150)

Subjects:

The Human Disharmony Loop (central). by James M. Friedman (22522150)

Subjects:

Sample Pain Diagrams. by James M. Friedman (22522150)

Subjects:

Patient Example. by James M. Friedman (22522150)

Subjects:

Summary of study eligibility criteria. by Biban Gill (1473337)

“…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …”

Summary of study participation and feasibility. by Biban Gill (1473337)

“…Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.</p><p>Methods</p><p>ACB women aged 18–49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.5mg/day); a vaginal probiotic (RepHresh™ Pro-B™) administered twice daily; a combination of Estring© and vaginal RepHresh™ Pro-B™ (twice daily); or the Estring© and oral RepHresh™ Pro-B™ (twice daily), for a duration of 30 days. …”

Sociodemographic and economic factors of study subjects, Ethiopia, EDHS 2005–2016 (N = 29,525). by Girma Beressa (9580436)

Subjects:

Multivariable multilevel mixed-effects logistic regression analyses of zinc utilisation and predictors among under-five children with diarrhoea, Ethiopia, 2005–2016 (N = 29,525). by Girma Beressa (9580436)

Subjects:

Frequency distribution of SOLEC at baseline and follow-ups in WAD grade 2 and WAD grade 3. by Anneli Peolsson (7867601)

Subjects:

The CONSORT flow diagram. by Anneli Peolsson (7867601)

Subjects:

Linear mixed model results, fixed effects for time points, group, time points x group and univariate effects in the two groups WAD grades 2 and 3. by Anneli Peolsson (7867601)

Subjects:

Baseline descriptive characteristics of trial participants (n = 140) with and without dizziness. by Anneli Peolsson (7867601)

Subjects:

Frequency distribution of SOLEC at baseline and follow-ups in the NSEIT and NSE groups. by Anneli Peolsson (7867601)

Subjects:

Outcomes in DHI score, dizziness and unsteadiness at baseline and at three- and 15-month follow-ups for each WAD group, and within-group effects. by Anneli Peolsson (7867601)

Subjects:

Baseline descriptive characteristics of trial participants with dizziness, by treatment group. by Anneli Peolsson (7867601)

Subjects:

Linear mixed model results, fixed effects for time points, group, time points x group and univariate effects in the neck-specific exercise with internet support (NSEIT) group and t... by Anneli Peolsson (7867601)

Subjects:

Outcomes in DHI score, dizziness and unsteadiness at baseline and at three- and 15-month follow-ups for each intervention group, and within-group effects. by Anneli Peolsson (7867601)

Subjects: